Orthofix Medical (NASDAQ:OFIX) Announces Earnings Results, Misses Expectations By $0.81 EPS

Orthofix Medical (NASDAQ:OFIX) posted its quarterly earnings data on Tuesday. The medical device company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.81), Zacks reports. Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $20.16 on Tuesday. The firm has a market cap of $770.20 million, a price-to-earnings ratio of -6.44 and a beta of 1.10. Orthofix Medical has a fifty-two week low of $12.08 and a fifty-two week high of $20.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The firm has a fifty day moving average price of $17.94 and a 200 day moving average price of $17.34.

Insider Activity

In related news, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now owns 28,312 shares in the company, valued at $506,501.68. This trade represents a 14.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $17.14, for a total value of $157,739.42. Following the completion of the sale, the chief executive officer now owns 124,151 shares of the company’s stock, valued at $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,442 shares of company stock worth $436,883 over the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Analysts Set New Price Targets

OFIX has been the subject of a number of analyst reports. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a report on Friday, January 31st. Roth Mkm reiterated a “buy” rating and issued a $22.00 price objective (up previously from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Canaccord Genuity Group started coverage on shares of Orthofix Medical in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.